On a positive note, Tandem Diabetes exited the second quarter with year-over-year sales growth. In the United States and Canada, the company's sales and clinical field teams have been flexible in successfully adjusting to the pandemic's complexity. Outside the United States, the company's distribution partners, despite experiencing COVID-related headwinds, continued to execute very well. Control-IQ was available in all the countries where the company serves and met with high levels of customer enthusiasm.